Related references
Note: Only part of the references are listed.Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
ZhengGang Ren et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Pregabalin for the Treatment of Painful Hand-Foot Skin Reaction Associated With Dabrafenib
Evelyn Lilly et al.
JAMA DERMATOLOGY (2015)
Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients
L. Vanneste et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma
N. Shinohara et al.
ANNALS OF ONCOLOGY (2014)
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
Arnoud J. Templeton et al.
BREAST (2014)
Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
J. Sastre et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2014)
An update on the safety and efficacy of regorafenib in the treatment of solid cancers
Stephen L. Chan et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma
Amrita Sil et al.
INDIAN JOURNAL OF PHARMACOLOGY (2014)
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
Roberta Schmieder et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
Yu Sunakawa et al.
INVESTIGATIONAL NEW DRUGS (2014)
Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management
Kristen K. Miller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care
Axel Grothey et al.
ONCOLOGIST (2014)
Prevention and management of adverse events related to regorafenib
Mieke De Wit et al.
SUPPORTIVE CARE IN CANCER (2014)
Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
Gazala Khan et al.
CANCER MANAGEMENT AND RESEARCH (2014)
Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic
Alyx C. Rosen et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2013)
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
L. Boussemart et al.
ANNALS OF ONCOLOGY (2013)
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma
Norihiko Tsuchiya et al.
ANTI-CANCER DRUGS (2013)
Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and Management
Viswanath Reddy Belum et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2013)
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
Jordi Bruix et al.
EUROPEAN JOURNAL OF CANCER (2013)
The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome
Nienke A. G. Lankheet et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis
Viswanath Reddy Belum et al.
INVESTIGATIONAL NEW DRUGS (2013)
HandFoot Skin Reaction is Associated with the Clinical Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib
Kazuhiko Nakano et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology
B. Dreno et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions
Jian-ri Li et al.
SUPPORTIVE CARE IN CANCER (2013)
Hand-foot syndrome with tyrosine kinase inhibitor therapy. Treatment recommendations
G. J. Burbach et al.
UROLOGE (2013)
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib
G. Dranitsaris et al.
ANNALS OF ONCOLOGY (2012)
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study
A. Poprach et al.
ANNALS OF ONCOLOGY (2012)
Topical Psoralen Plus UV-A Therapy for Tyrosine Kinase Inhibitor–Induced Hand-Foot Syndrome
ARCHIVES OF DERMATOLOGY (2012)
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
D. Strumberg et al.
BRITISH JOURNAL OF CANCER (2012)
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen
Carlos Gomez-Martin et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2012)
Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
Taiga Otsuka et al.
HEPATOLOGY RESEARCH (2012)
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy
Chih-Tsung Hung et al.
JOURNAL OF DERMATOLOGY (2012)
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial
Tim Eisen et al.
LANCET ONCOLOGY (2012)
Capecitabine-Induced Hand-Foot Syndrome Complicated by Pseudomonal Superinfection Resulting in Bacterial Sepsis and Death Case Report and Review of the Literature
Fridolin J. Hoesly et al.
ARCHIVES OF DERMATOLOGY (2011)
Economic Burden of Dermatologic Adverse Events Induced by Molecularly Targeted Cancer Agents
Judy H. Borovicka et al.
ARCHIVES OF DERMATOLOGY (2011)
Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib
Beth McLellan et al.
DERMATOLOGIC THERAPY (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Determination of Sunitinib and Its Active Metabolite N-Desethylsunitinib in Sweat of a Patient
Nienke A. G. Lankheet et al.
JOURNAL OF ANALYTICAL TOXICOLOGY (2011)
Clinical Presentation and Management of Hand-Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic Chemotherapy: Experience in Breast Cancer
Patricia Gomez et al.
ONCOLOGIST (2011)
HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand-Foot Syndrome
Vincent Sibaud et al.
ONCOLOGIST (2011)
Skin care management in cancer patients: an evaluation of quality of life and tolerability
Ann Cameron Haley et al.
SUPPORTIVE CARE IN CANCER (2011)
Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma
Chih-Hsun Yang et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
Lokesh Jain et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Lack of Association Between Excretion of Sorafenib in Sweat and Hand-Foot Skin Reaction
Lokesh Jain et al.
PHARMACOTHERAPY (2010)
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
W. J. Lee et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy
Nilofer S. Azad et al.
CLINICAL CANCER RESEARCH (2009)
Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non-Renal Cell Carcinoma: A Meta-analysis
David Chu et al.
CLINICAL GENITOURINARY CANCER (2009)
Blackberry-induced hand-foot skin reaction to sunitinib
Susan L. Boone et al.
INVESTIGATIONAL NEW DRUGS (2009)
Dermatologic symptoms associated with the multikinase inhibitor sorafenib
Caroline Robert et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Search for Evidence-Based Approaches for the Prevention and Palliation of Hand-Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)
Roger Anderson et al.
ONCOLOGIST (2009)
Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
Adam D. Lipworth et al.
ONCOLOGY (2009)
Successful Topical Treatment of Sorafenib-Induced Hand-Foot Skin Reaction in a Child with Hepatocellular Carcinoma
MATTHIAS HÜTTEN et al.
PEDIATRIC DERMATOLOGY (2009)
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
V. Sibaud et al.
TARGETED ONCOLOGY (2009)
Span-planting cutaneous reaction secondary to sorafenib
B. Echeverria et al.
ACTAS DERMO-SIFILIOGRAFICAS (2009)
Risk of hand-foot skin reaction with sorafenibo: A systematic review and metes-analysis
David Chu et al.
ACTA ONCOLOGICA (2008)
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib
M. E. Lacouture et al.
ANNALS OF ONCOLOGY (2008)
Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib
Mario E. Lacouture et al.
ONCOLOGIST (2008)
Influence of skin color in the development of erlotinib-induced rash: A report from the SERIES clinic
S. E. Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hand-foot and stump syndrome to sorafenib
Susan E. Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Release of doxorubicin in sweat:: first step to induce the palmarplantar erythrodysesthesia syndrome?
U Jacobi et al.
ANNALS OF ONCOLOGY (2005)
10 years experience of the Dermatology Life Quality Index (DLQI)
V Lewis et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2004)
Share Paper
